Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279Silvana Leit, C. E. Masse, Shulu Feng et al.|Journal of Medicinal Chemistry|2023Cited by 60
Abstract 942: HPK1, hematopoietic progenitor kinase 1, is a promising therapeutic target for cancer immunotherapyDavid Ciccone, Neelu Kaila, Vad Lazari et al.|Cancer Research|2020Cited by 1
A highly selective and potent HPK1 inhibitor enhances immune cell activation and induces robust tumor growth inhibition in a murine syngeneic tumor modelDavid Ciccone, Neelu Kaila, Vad Lazari et al.|European Journal of Cancer|2020Cited by 1
685 A highly selective and potent HPK1 inhibitor enhances immune cell activation and induces robust tumor growth inhibition in a murine syngeneic tumor modelDavid Ciccone, Neelu Kaila, Vad Lazari et al.|Regular and Young Investigator Award Abstracts|2020Cited by 1
Abstract 1649: Mechanistic understanding of HPK1 inhibition on enhanced human T cell activation and tumor immunity in a syngeneic modelDavid Ciccone, Neelu Kaila, Vad Lazari et al.|Cancer Research|2021Cited by 1